Showing posts with label biopharmaceutical. Show all posts
Showing posts with label biopharmaceutical. Show all posts

Tuesday, April 26, 2016

Cell Culture Media: Balancing Resources with Results

Why does medium matter?


It all starts with media. Without an appropriate growth medium, no biopharmaceutical process would exist. The proper medium allows for cells to grow and generate product. Going beyond the fact that cell culture processes would simply not exist without cell culture media, the medium (and associated feeds for fed-batch processes) represents a large portion of the cost of a biopharmaceutical process. Cell culture media are complex entities that encompass large quantities of raw materials as well as a high level of technical expertise, driving up the cost per litre.


What are the advantages of an optimized medium formulation compared to an off the shelf product? 

Many people will choose to start with standard off the shelf products for their cell culture processes. While there are a wide variety of products available on the market, there are several important reasons to consider using an optimized medium formulation instead. The first is to tailor a medium formulation specifically for your own cell line. Every cell line will respond differently to standard products, and optimizing a medium formulation is the best way to ensure that you use a medium that works best for your application and requirements. Additionally, as you generate different cell lines with varying genetic constructs for new products, your cells may begin to respond differently. Having an optimized medium formulation allows you to adapt to these changes while maintaining growth and productivity. Using a standard product also means you are bound to a single vendor with no access to proprietary formulations. With your own optimized medium, you have full access to the formulation, with the ability to manufacture it with a vendor of your choice.


What factors should I consider when developing an optimized medium?


As discussed previously, optimizing a medium formulation to get you the best growth and productivity is the main driving factor, and allows you to minimize the amount of medium used and therefore your overall COGS. It is important to also consider what the criteria are for your optimized medium. For many industries, having a fully chemically defined, non-animal origin medium is critical. This minimizes lot to lot variability and is highly desirable from a regulatory standpoint. Ease of use is also important to consider. This encompasses storage aspects, such as shelf life, and shipping and handling conditions. Ease of use also involves simplifying the process for the operator. As media and feeds become increasingly complex, how difficult does it become to formulate? Will operators have to perform risky pH adjustments with large volumes of corrosive reagents? Will high temperatures be needed to dissolve certain components, and can these high temperatures be achieved as the industry moves towards more single-use technologies? These and other factors must be considered when developing an optimized medium formulation.


What resources are required to develop an optimized medium?


The actual raw materials that form the bulk of a cell culture medium are generally inexpensive. The resources required for an optimized medium formulation that drive up the ultimate cost per liter are time, personnel, equipment, and expertise. With the increasing use of multivariate approaches (Design of Experiments, Principal Component Analysis), the use of high throughput systems become highly advantageous, reducing personnel requirements. Finally, expertise in media development is something that comes only with years of experience in the industry and cannot be bought with any amount of money.


So how do I develop an optimized medium formulation?


There are several approaches to media optimization. Some methods include titration, reverse engineering of other media, and metabolomics. While some of these methods are effective, when implemented on their own, they are time consuming, labor intensive, and heavily resource-dependent. A modern, DoE based approach to media development for CHO based processes is the CHOptimizer® Media Builder. CHOptimizer® consists of three distinct phases. The package is designed to be integrated into our ambr™15 system for automation and ease of use. In the first phase, four chemically defined, non-animal origin based media are blended in different ratios, according to a mixtures design DoE approach. Subsequent phases incorporate spent media analysis and fractional factorial DoE approaches to develop an optimized medium formulation, feed formulation, and corresponding feeding strategy. CHOptimizer® base media are developed using the expertise of Lonza Biologics, and combines a modern, high throughput approach with traditional ideas to deliver an optimized medium in a short timeline, with field based support. It also offers full access to the formulation for ultimate flexibility in the future.

To learn more about CHO media optimization join Sartorius Stedim Biotech’s workshop, chaired by Dr. Michael Gillmeister, Lonza at the IBC Cell Line Development & Engineering Conference, San Francisco, 13th June at 11.45am.


About the author:
Dr. Michael Gillmeister received his Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University in collaboration with the University of Maryland School of Medicine specializing in glycosylation, transient protein production, and neurobiology. In 2009, Mike joined the Gibco® research and development group and was responsible for next-generation media and sera projects. He then led media and process development projects to modulate product quality and maximize titer for PD-Direct® Custom Media Services using high-throughput and bioreactor technologies. Currently, Mike leads Protein Expression Media R&D and the CHOptimizer™ media optimization service for Lonza Walkersville.


Share this article with your social network, just click below to share now!


Monday, February 29, 2016

Innovative Technologies, People, and Organizations Drive the Future of Bioprocessing

By  S. Anne Montgomery, Editor in Chief, BioProcess International 

In the 14 years that BioProcess International (BPI) magazine has been around, the biopharmaceutical industry has experienced a dramatic confluence of technologies, analytics, and regulatory initiatives aimed toward accelerating development and commercialization of life-saving biotherapeutics. Although a number of these topics were “on the radar” before the turn of the century, by the time of BPI’s first issue in January of 2003, they were beginning to be discussed in earnest, and references to “disruptive technologies” began to appear in print, online, and conference discussions across development phases.

As revealed in BPI’s article archive the list is impressive and includes, notably
• single-use technologies
• quality-by-design
• process-analytical technologies
• advanced medicines/cell and gene therapies
• antibody–drug conjugates
• biosimilars and biobetters
• immunotherapies
• combination products
• companion diagnostics
• platform analytics and manufacturing technologies
• product life-cycle development
• continuous processing.

We have watched, too, as those innovations spread across the globe into regions not previously considered to be biomanufacturing hubs and as international regulatory agencies sought to harmonize pathways to approval. Different partnering models have emerged with both long- and short-term goals, but many in response to concerns about supply-chain integrity in an era of life-cycle management.

Presenting information and guidance for sorting through these choices of platforms, technologies, and manufacturing models is the continuing work of technical publications and conference presentations. BioProcess International magazine has always benefited from its close collaboration with the Informa conference groups (IIR/IBC) to create separate but compatible content and presentation vehicles. Many of the magazine’s editorial advisors also have served on the conference advisory panels, for example, and industry trends (and the best people to speak and write about them) identified by one group are shared with the other to bring as consistent a message to our readers and event attendees as possible.

Our two annual flagship events — now called BPI West and BPI — pull these interrelated topics together into week-long programs that you don’t want to miss if you need to stay on top of the latest interpretations of these trends. A quick look at the program for the upcoming BPI West (14–17 March 2016 in Oakland, CA) reveals the ongoing impact of the past decade’s advances on the current biopharmaceutical industry. The opening preconference symposia in themselves reflect key areas of attention: innovative approaches and technologies in process development and manufacturing, cell-therapy commercialization, ADC development, and continuous processing. Many elements of those topics were just promising ideas a decade ago, research topics that “might someday” be brought into commercial viability.

Another example is that the Basic Research and Discovery track of this year’s conference is far from the relatively “siloed” research presentations of the past. Speakers here now will stress the needed overlap of development strategies with early risk analysis and process optimization — with their goals (repeating across product classes and development stages) of shortening the times for lead optimization and transition into manufacturing. Enabling technologies incorporate analytical tools that in themselves introduce new questions: How much information is too much? What are we seeing now of contaminants and particulates in marketed products that we didn’t know were there before, and what does that mean for developers of follow-on products? What statistical knowledge for assessing this wealth of data is now required of those entering the industry that was not deemed necessary before?

I urge you to visit the conference site, download the program, and plan to attend sessions that will help you navigate the current and future worlds of biomanufacturing. Network with your peers, among whom are many veterans who helped build our current industry as well as a younger generation who are introducing fresh insights and new ways of implementing technologies and communication tools.

And as you contribute to advancing this new world biomedical approaches, take a look, also, at BPI’s third biennual awards program categories. Our awards are designed to reflect key milestones in the industry, highlight technologies that are making often-disruptive changes in how biopharmaceutical products and modalities are reaching those who desperately need them, and honor companies and people who are building a new world of healthcare options for both regional and global communities.

I have followed the biopharmaceutical industry as an editor since 1988, and I sometimes take a step back and marvel at how far this work has come. Technologies come and go — and some return again, with problems solved and new challenges revealed. Terminology may look the same, but its connotations are sometimes radically different to new generations. As always, communication is key, but exchange of knowledge must be based on shared understanding of terminology and technologies. Plan to join us in March and continue to contribute to these meaningful discussions. Make your mark on the future of biomanufacturing — we need your voice and we want to hear about your experiences.


Share this article with your social network, just click below to share now!


Wednesday, February 3, 2016

[Survey] Bioprocessing Efficiency | Enter for a Chance to Win









Maximize Efficiency; Streamline Biopharmaceutical Process Development & Production 

One of the major goals of BPI West it to provide information that you can use to streamline and accelerate process development and production to maximize efficiency from basic research to commercial manufacturing. With that in mind, we would greatly appreciate a few moments of your time to answer the following questions to help us better understand your needs and approaches to accomplishing these goals.


Upon completing the survey, you will be entered into a drawing to win an all-access pass* to BPI West, taking place in Oakland, CA March 14-17, 2016. Learn more about BPI West.

The compiled results of this survey will be distributed as a detailed infographic reportt, depicting the current state and future directions of the biopharmaceutical industry.

We truly value the information you have provided and thank you in advance for taking the time out of your busy day to participate in our survey.

*Offer is not valid for existing or pending registrations, and cannot be retroactively applied. IBC USA & BPI West are not responsible for any hotel or travel costs.


Share this article with your social network, just click below to share now!


Friday, January 8, 2016

Leaders from Amgen and Celltheon Set to Keynote BPI West

Specialists from every discipline and stage of development aim to achieve the common goals of optimizing speed, reducing cost, and improving quality from basic research to commercialization. What helps the learning curve is to benchmark best practices from the exclusive experience of the top minds in the biopharmaceutical industry.

The leading experts from Amgen and CellTheon will get together at BPI West in Oakland, CA (March 14-17, 2016) to share their exclusive case studies and new data and evaluate the different approaches that are being utilized to streamline and accelerate development and production across:

- Basic Research & Discovery
- Early Stage Process Development & Pre-Clinical Manufacturing
- Late Stage Process Development & Clinical Manufacturing
- Commercial Manufacturing & Beyond

The following keynotes have been announced:



Amita Goel, MSc. Founder, and CEO, Celltheon will be presenting on Innovative Technologies for the Expression of Next Generation Bio Therapeutics;


Rohini Deshpande, Ph.D. Executive Director, Process and Product Development, Amgen will give a talk on End-to-End Integration;



Ran Zheng, Ph.D., Executive Director, Plant Manager, Amgen is joining BPI West with a presentation called “Unleashing the Power of Innovation to Tackle Biomanufacturing's Greatest Challenges, Fuel Growth and Drive Value Creation.”


To see more speakers and to get the most up-to-date brochure, click here
Don’t miss the chance to learn the innovative strategies and technologies and help move the pipeline of next generation drug candidates closer to approval!

Register before Friday, January 22nd and save $400 – Simply use the code BPIWEST16BL, to save. 



Share this article with your social network, just click below to share now!


Monday, August 3, 2015

Increasing the flexibility of fill finish operations with single-use technology

There are many benefits to using single-use technology for the manufacture of biopharmaceuticals. The enabling aspect of the technology that allows closed-system processing has been examined in a previous postThe single-use principle can be applied across the biomanufacturing process with bioreactors, chromatography and cross flow filtration all available in single-use formats.

Single-Use and Fill Finish

The role of single-use in adding flexibility to fill finish operations will be the subject of a presentation given by Chris Smalley, Ph.D., from Merck & Co. at the Bioprocess International 2015 Conference that will be held in Boston in October. Chris’presentation will be part of the ‘Drug Product Manufacturing & Fill-Finish Processing’ track which is new for this year.

In a recent interview, Chris highlighted the fact that single-use technologies can play an important role in helping to rapidly establish global networks of fill finish operations. These are required in order to meet emerging demands (Merck Champions Single-Use ByAddressing Emotion Vs. Science, by Trisha Gladd at Bioprocess Online)

One way of developing such a network will be to utilize existing manufacturing locations and staff. Minimizing the amount of work required to redevelop these existing facilities around the world will be crucial in achieving the level of operational agility that will likely be required. Taking a single-use approach to fill finish will allow this by reducing the need for HVAC, cleanrooms and WFI systems. The affordability of drugs can be improved as the capital costs, labor requirements and time needed to design and build new facilities will be reduced.

Particulates and Extractables

In the article, Smalley addresses two common concerns about single-use technologies that are particularly pertinent during fill finish operations, namely, particulates and extractables. These are especially important issues for fill finish because there are no further processing steps that can remove impurities derived from equipment or consumables at this stage in the process. Smalley believes that the available studies show that there is little or no risk to patients from particulates and he is an advocate of suppliers providing adopting the BPOG guidelines with respect to extractables.

To facilitate the implementation of single-use across the company, Merck have a Single-Use Network (SUN) of advocates that set guidelines and define good practices. Smalley sees standardization as a key success factor for single-use implementation within the industry. He will no doubt be interested in participating in the Town Hall Forum Discussion on single-use technologies with industry organizations such as BPSA, BPOG, PDA, ASME BPE and ASTM.

Have your say

To what extent do you think challenges, such as particulates and extractables, relating to the implementation of single-use technologies can be overcome?


Join me at #BPIconf
Contact me at nick.hutchinson@parker.com


Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Monday, June 15, 2015

BPI 2015 Final program just released!



BPI is engineered to be exactly what YOU need it to be. Formal and informal networking experiences connect you to peers, prospects, and customers. Parallel tracks give you the option to dive deep or take a big picture approach to learn about industry trends, challenges, and benchmark against the latest research developments. Big pharma and large, mid-size and emerging biotechs collaborating with solution providers featuring proven and next generation technologies make BPI a one-of-a-kind meeting place.


Bioprocess International
Conference & Exposition
October 26-29, 2015
Hynes Convention Center
Boston, MA


Download the brochure here: >>> http://bit.ly/1K9ELmX
Use code XB15171BLOG for $100 off the current rate.

The Most Comprehensive Science: Capitalize on the latest data-driven research and moderated discussions to move towards commercialization and streamlined development and production from upstream to drug product/fill-finish. 

The Most Innovative Technologies: Accelerate speed, efficiency and ROI across a global network by evaluating innovative and proven products and services at the industry’s largest exposition.
 
The Right Partners for You: Form collaborations and alliances with innovators, suppliers, academia and associations to reach new heights of clinical and commercial success. 

Gain Access to 6 Conference Tracks with 1 Registration Fee:
  • Cell Culture & Upstream Processing;
  • Recovery & Purification;
  • Manufacturing Strategy;
  • Analytical, Formulation and Quality;
  • Drug Product Manufacturing & Fill-Finish Processing;
  • Early Stage Biologics and Early Stage Companies.   
 Meet the People Behind the Products and Get the Answers You Need!

In the largest exposition hall devoted exclusively to biopharmaceutical manufacturing, attendees will learn about the latest technologies and services developed to overcome challenges and streamline processes. Network and consult with the experts from product and service provider companies.

Download the brochure to learn more: >>> http://bit.ly/1K9ELmX

Register by Friday, June 12 to Receive Up To a $500 Savings
Your Savings Code = XB15171BLOG

Register now to save up to $500 here >>> http://bit.ly/1demU18


Group Rates Available for Companies Registering 4+ Attendees.
Call Millison Thenor directly at 646-895-7423.

*Discount is valid for new registrations only and cannot be combined with any other offer.

Best,
The BPI 2015 Team.
@IBCBioProcess
#BPIconf
www.IBCLifeSciences.com/BPI



Share this article with your social network, just click below to share now!


Wednesday, April 8, 2015

BDP Week 2015: Conventional vs Single-Use Facilities Panel Discussion

By: Maribel Rios, Managing Editor of BioProcess International

On Wednesday, 1 April 2015, the Biopharmaceutical Development and Production Week meeting held a Q&A session between attendees and a selected panel, moderated by Adam Goldstein (Genentech, a member of the Roche group). Panelists included Nuno Fontes (Boehringer Ingelheim), David Fritsch (Fritsh Consulting), Francis Kobina Insaidoo, PhD (Merck Research Laboratories), Chris Antoniou (Biogen Idec), and James D. Vogel (The BioProcess Institute). The panel first discussed the merits of moving to an all-single-use facility, such as Amgen’s facility in Singapore as opposed to continuing to use a stainless-steel-based facility and making modifications with single-use systems. Questions and discussion focused on the following:

·         Does building a complete single-use facility make sense? The panel agreed that there are some processes (e.g., early stage, smaller volume, pilot studies) in which the complete or near-complete use of single-use systems make sense. Larger-volumen(>2,000 L), commercial-scale, and dedicated processes would be more susceptible for stainless-steel systems.
·         How does cost of goods and other economic factors play a role? The panel agreed that manufacturers must examine all factors carefully, including timelines for building a facility. Other concepts, such as ballroom-style or modular facilities also can reduce timelines.
·         Are there single-use solutions for high cell density and high-titer processes? And are there ideas for addressing the limitations of single-use mixing of such processes? The panel responded that work on “loop” systems is ongoing through companies such as HyClone/Thermo/GE.




Share this article with your social network, just click below to share now!


Tuesday, March 31, 2015

BDP Week 2015: BPSA Roundtable

By: Maribel Rios, Managing Editor of BioProcess International

The Bio-Process Systems Alliance (BPSA) presented a single-use applications roundtable on Monday, 30 March 2015, at the BioPharmaceutical Development and Production (BDP) Week meeting in Huntington Beach, California. Mark Petrich, PhD (Merck & Co., Inc.) moderated the panel consisting of Jerry Martin (Pall Corporation), Jeffrey Carter, PhD (GE Healthcare), James Vogel (The BioProcess Institute), and Todd A. Kapp (Parker-Hannifin Corporation). Martin started with a historical review of the BPSA, a trade organization formed in 2005 and now consisting of 46 member companies (suppliers and end users) whose goal is to “advance single-use worldwide and facilitate implementation of single-use technologies.” 

Carter and Vogel then reviewed BPSA’s active and recent projects, consisting of the following:
·         Single-Use Manufacturing Component Quality Test Matrices (currently under final review and should be available for the BPSA Annual Summit, 13-15 July 2015, in Washington DC)
·         Change Notification Practices (currently in the initial stages of documenting)
·         Extractables (currently continuing collaboration with other organizations such as ASTM, ASME-BPE, and USP)

·         Quality Agreement Template for Single-Use Biopharmaceutial Manufacturing Products (published July 2014, currently soliciting feedback from users of the template, with possible future revisions)
·         Particulates Guide, a 12-chapter compendium addressing why particulates are an issue, how to identify them, and so on (currently soliciting further input)

The roundtable concluded with Knapp presenting the future focus of BPSA, including the annual summit and its new scholarship fund.


Share this article with your social network, just click below to share now!


Thursday, August 28, 2014

Due Diligence of Early Stage Technologies: Achieving Rapid Product Development with Low R&D Costs

Today, we feature an article from our partners at BioProcess International Magazine. This is an excerpt from the article Due Diligence of Early Stage Technologies: Achieving Rapid Product Development with Low R&D Costs.



BPI_A_141206AR01_O_F0001Increased understanding of human diseases at molecular and cellular levels is leading to development of novel life-science technologies. Such advancements typically pertain to discovery and manufacturing of novel human therapeutics, new modes of drug delivery, and novel diagnostic technologies. The majority of those technologies are developed by early stage biopharmaceutical companies that have a greater appetite for risk than do larger companies.

Early stage biopharmaceutical companies, however, have limited capital raised through personal sources, angel investors, venture capital, or government grants. So these companies usually focus on a single product or technology. As a result, their survival is contingent upon demonstrating successful product development within available capital.

A number of statistics have been cited about the survival and success rates of early stage biotechnology companies. Nearly all authors agree that the majority of those companies do not attain success and that poor management is a key reason for most failures. SMC Consulting Group (SMC) has identified critical management factors contributing to the failure of early stage biotechnology companies. Among these is insufficient early planning, specifically the following:
  • - Lack of a detailed target product profile
  • - Limited planning for product development from research through clinical manufacturing in early stages of development
  • - Limited financial potential or lower probability of success for a selected target disease area
  • Limited differentiation of a target product from other products developed by competitors.
Without detailed target product profiles and pre-development planning, early stage biotechnology companies spend valuable and limited time and resources non-productively. SMC recommends that such companies perform comprehensive due diligence to develop target product profiles and plan their development processes before initiating research and development (R&D) activities. To learn more, 

Read the full article here.

You can find out more about topics like this and meet and network with other professionals in the bioprocessing field at this year's BioProcess International Conference and Exhibition.  As a reader of this blog, when you register to join us October 20-23 in Boston, you are eligible to receive 20% off the standard rate when you mention code BPI14BLOG.


Share this article with your social network, just click below to share now!